{"success":true,"data":{"pressRelease":{"id":"127110","rtpr_id":"nGNEc1kXbK","ticker":"GMAB","exchange":"NASDAQ","all_tickers":["GMAB"],"title":"REG-Genmab to Participate in Upcoming Investor Conferences","author":"Globe Newswire","published_at":"2026-08-25T12:59:59.864Z","article_body":"Media Release\n\nCOPENHAGEN, Denmark; August 25, 2026\n\nGenmab A/S\n(https://www.globenewswire.com/Tracker?data=WQIJqY7glwfPdiaBQsqYJLYwWPaASxCk6TEUsCeANX7Yeon9IV99c6W-F0-Solt3qvXRnm_ruzomELD0N8Nnxw==)\n(Nasdaq: GMAB) announced today that members of its Executive Committee will\nparticipate in fireside chats at the following investor conferences in\nSeptember 2026: \n* Wells Fargo 21st Annual Healthcare Conference in Boston on September 9,\n2026, 3:00 PM EDT\n* 24th Annual Morgan Stanley Global Healthcare Conference in New York City on\nSeptember 15, 2026, 8:30 AM EDT\n* Bank of America Global Healthcare Conference in London on September 22,\n2026, 10:55 AM BST\nThe live and archived webcast of the presentations will be available on\nGenmab’s website at https://ir.genmab.com/events-presentations.\n\nAbout Genmab \nGenmab is an international biotechnology company with a core purpose of\nguiding its unstoppable team to strive toward improving the lives of patients\nwith innovative and differentiated antibody therapeutics. For more than 25\nyears, its passionate, innovative and collaborative team has invented\nnext-generation antibody technology platforms and leveraged translational,\nquantitative and data sciences, resulting in a proprietary pipeline including\nbispecific T-cell engagers, antibody-drug conjugates, next-generation immune\ncheckpoint modulators and effector function-enhanced antibodies. By 2030,\nGenmab’s vision is to transform the lives of people with cancer and other\nserious diseases with knock-your-socks-off (KYSO) antibody medicines(®). \n\nEstablished in 1999, Genmab is headquartered in Copenhagen, Denmark, with\ninternational presence across North America, Europe and Asia Pacific. For more\ninformation, please visit Genmab.com\n(https://www.globenewswire.com/Tracker?data=WQIJqY7glwfPdiaBQsqYJEUtwdxTjE2hgwzO3f1NfEdaySI1Xye9Gmlc92riftqCThUUJyAYVMfesLO7cgP_1IhCaw2gH9pHGdBC13zRBWhTyFhq7B9WuQEkmukUHRenbaYcyCobFuuWEZeLE2Ht99rBQfWXh-j_3G1RDKysECi6ZAL8DGbLqtg2QZpgNGW4BnLKp0AuGIOMrghBVynxXXUWH2VYA8H_99N3JvbIBxA=) and\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ieiidCs2vT-imvOWlySJqvqie57q2CtXZwjIp-6krxIU00vjyI7y49EPKvRKuTZ1AbKmWdH9oIgYzcHbPuaaWWFObX5OKCLvkzxT_Myln6c=)\nand X\n(https://www.globenewswire.com/Tracker?data=SFhUWhF8sd0yDO3L9IEutSP5Adem8WzD01MkX7aKNx9u8M22pIiclHgLf8gWdlVg6edAIOJ0IcFFpdbSRM0uSA==).\n\nContact:        \nMarisol Peron, Senior Vice President, Global Communications & Corporate\nAffairs\nT: +1 609 524 0065; E: mmp@genmab.com\n\nAndrew Carlsen, Vice President, Head of Investor Relations\nT: +45 3377 9558; E: acn@genmab.com\n\nThis Media Release contains forward looking statements. The words\n“believe,” “expect,” “anticipate,” “intend” and “plan” and\nsimilar expressions identify forward looking statements. Actual results or\nperformance may differ materially from any future results or performance\nexpressed or implied by such statements. The important factors that could\ncause our actual results or performance to differ materially include, among\nothers, risks associated with preclinical and clinical development of\nproducts, uncertainties related to the outcome and conduct of clinical trials\nincluding unforeseen safety issues, uncertainties related to product\nmanufacturing, the lack of market acceptance of our products, our inability to\nmanage growth, the competitive environment in relation to our business area\nand markets, our inability to attract and retain suitably qualified personnel,\nthe unenforceability or lack of protection of our patents and proprietary\nrights, our relationships with affiliated entities, changes and developments\nin technology which may render our products or technologies obsolete, and\nother factors. For a further discussion of these risks, please refer to the\nrisk management sections in Genmab’s most recent financial reports, which\nare available on www.genmab.com and the risk factors included in Genmab’s\nmost recent Annual Report on Form 20-F and other filings with the U.S.\nSecurities and Exchange Commission (SEC), which are available at www.sec.gov.\nGenmab does not undertake any obligation to update or revise forward looking\nstatements in this Media Release nor to confirm such statements to reflect\nsubsequent events or circumstances after the date made or in relation to\nactual results, unless required by law.\n\nGenmab A/S and/or its subsidiaries own the following trademarks: Genmab(®);\nthe Y-shaped Genmab logo(®); Genmab in combination with the Y-shaped Genmab\nlogo(®); HuMax(®); DuoBody(®); HexaBody(®); DuoHexaBody(®), HexElect(®)\nand KYSO(®).\n\nMedia Release no. 11\nCVR no. 2102 3884\nLEI Code 529900MTJPDPE4MHJ122\n\nGenmab A/S\nCarl Jacobsens Vej 30\n2500 Valby\nDenmark\n\n\n\nAttachment\n*     082526_i11_Sept\n(https://ml-eu.globenewswire.com/Resource/Download/6703c3d3-318c-4d45-aa44-a03bc3eae46c)","article_body_html":"","raw_payload":{"data":{"id":"nGNEc1kXbK","title":"REG-Genmab to Participate in Upcoming Investor Conferences","author":"Globe Newswire","ticker":"GMAB","created":"2026-08-25T12:59:59.864Z","tickers":["GMAB"],"exchange":"NASDAQ","article_body":"Media Release\n\nCOPENHAGEN, Denmark; August 25, 2026\n\nGenmab A/S\n(https://www.globenewswire.com/Tracker?data=WQIJqY7glwfPdiaBQsqYJLYwWPaASxCk6TEUsCeANX7Yeon9IV99c6W-F0-Solt3qvXRnm_ruzomELD0N8Nnxw==)\n(Nasdaq: GMAB) announced today that members of its Executive Committee will\nparticipate in fireside chats at the following investor conferences in\nSeptember 2026: \n* Wells Fargo 21st Annual Healthcare Conference in Boston on September 9,\n2026, 3:00 PM EDT\n* 24th Annual Morgan Stanley Global Healthcare Conference in New York City on\nSeptember 15, 2026, 8:30 AM EDT\n* Bank of America Global Healthcare Conference in London on September 22,\n2026, 10:55 AM BST\nThe live and archived webcast of the presentations will be available on\nGenmab’s website at https://ir.genmab.com/events-presentations.\n\nAbout Genmab \nGenmab is an international biotechnology company with a core purpose of\nguiding its unstoppable team to strive toward improving the lives of patients\nwith innovative and differentiated antibody therapeutics. For more than 25\nyears, its passionate, innovative and collaborative team has invented\nnext-generation antibody technology platforms and leveraged translational,\nquantitative and data sciences, resulting in a proprietary pipeline including\nbispecific T-cell engagers, antibody-drug conjugates, next-generation immune\ncheckpoint modulators and effector function-enhanced antibodies. By 2030,\nGenmab’s vision is to transform the lives of people with cancer and other\nserious diseases with knock-your-socks-off (KYSO) antibody medicines(®). \n\nEstablished in 1999, Genmab is headquartered in Copenhagen, Denmark, with\ninternational presence across North America, Europe and Asia Pacific. For more\ninformation, please visit Genmab.com\n(https://www.globenewswire.com/Tracker?data=WQIJqY7glwfPdiaBQsqYJEUtwdxTjE2hgwzO3f1NfEdaySI1Xye9Gmlc92riftqCThUUJyAYVMfesLO7cgP_1IhCaw2gH9pHGdBC13zRBWhTyFhq7B9WuQEkmukUHRenbaYcyCobFuuWEZeLE2Ht99rBQfWXh-j_3G1RDKysECi6ZAL8DGbLqtg2QZpgNGW4BnLKp0AuGIOMrghBVynxXXUWH2VYA8H_99N3JvbIBxA=) and\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ieiidCs2vT-imvOWlySJqvqie57q2CtXZwjIp-6krxIU00vjyI7y49EPKvRKuTZ1AbKmWdH9oIgYzcHbPuaaWWFObX5OKCLvkzxT_Myln6c=)\nand X\n(https://www.globenewswire.com/Tracker?data=SFhUWhF8sd0yDO3L9IEutSP5Adem8WzD01MkX7aKNx9u8M22pIiclHgLf8gWdlVg6edAIOJ0IcFFpdbSRM0uSA==).\n\nContact:        \nMarisol Peron, Senior Vice President, Global Communications & Corporate\nAffairs\nT: +1 609 524 0065; E: mmp@genmab.com\n\nAndrew Carlsen, Vice President, Head of Investor Relations\nT: +45 3377 9558; E: acn@genmab.com\n\nThis Media Release contains forward looking statements. The words\n“believe,” “expect,” “anticipate,” “intend” and “plan” and\nsimilar expressions identify forward looking statements. Actual results or\nperformance may differ materially from any future results or performance\nexpressed or implied by such statements. The important factors that could\ncause our actual results or performance to differ materially include, among\nothers, risks associated with preclinical and clinical development of\nproducts, uncertainties related to the outcome and conduct of clinical trials\nincluding unforeseen safety issues, uncertainties related to product\nmanufacturing, the lack of market acceptance of our products, our inability to\nmanage growth, the competitive environment in relation to our business area\nand markets, our inability to attract and retain suitably qualified personnel,\nthe unenforceability or lack of protection of our patents and proprietary\nrights, our relationships with affiliated entities, changes and developments\nin technology which may render our products or technologies obsolete, and\nother factors. For a further discussion of these risks, please refer to the\nrisk management sections in Genmab’s most recent financial reports, which\nare available on www.genmab.com and the risk factors included in Genmab’s\nmost recent Annual Report on Form 20-F and other filings with the U.S.\nSecurities and Exchange Commission (SEC), which are available at www.sec.gov.\nGenmab does not undertake any obligation to update or revise forward looking\nstatements in this Media Release nor to confirm such statements to reflect\nsubsequent events or circumstances after the date made or in relation to\nactual results, unless required by law.\n\nGenmab A/S and/or its subsidiaries own the following trademarks: Genmab(®);\nthe Y-shaped Genmab logo(®); Genmab in combination with the Y-shaped Genmab\nlogo(®); HuMax(®); DuoBody(®); HexaBody(®); DuoHexaBody(®), HexElect(®)\nand KYSO(®).\n\nMedia Release no. 11\nCVR no. 2102 3884\nLEI Code 529900MTJPDPE4MHJ122\n\nGenmab A/S\nCarl Jacobsens Vej 30\n2500 Valby\nDenmark\n\n\n\nAttachment\n*     082526_i11_Sept\n(https://ml-eu.globenewswire.com/Resource/Download/6703c3d3-318c-4d45-aa44-a03bc3eae46c)"},"type":"article","timestamp":"2026-08-25T12:59:59.961440745Z","server_sent_at_ms":1787662799961},"received_at":"2026-08-25T13:00:00.013Z","source_url":null},"analysis":{"id":"116036","press_release_id":"127110","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Genmab announced that members of its Executive Committee will participate in fireside chats at three upcoming investor conferences in September 2026.\n\nThe conferences include the Wells Fargo 21st Annual Healthcare Conference in Boston, the Morgan Stanley Global Healthcare Conference in New York City, and the Bank of America Global Healthcare Conference in London.\n\nLive and archived webcasts of these presentations will be available on the company's investor relations website.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference participation announcement; no material news."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Marisol Peron","role":"Senior Vice President, Global Communications & Corporate Affairs"},{"name":"Andrew Carlsen","role":"Vice President, Head of Investor Relations"}],"products":["bispecific T-cell engagers","antibody-drug conjugates","next-generation immune checkpoint modulators","effector function-enhanced antibodies"],"companies":[{"name":"Genmab A/S","ticker":"GMAB"},{"name":"Wells Fargo","relationship":"conference organizer"},{"name":"Morgan Stanley","relationship":"conference organizer"},{"name":"Bank of America","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine notification of participation in investor conferences. No new financial data, clinical results, or business developments announced."},"tickerRelevance":{"others":[],"primary":"GMAB"},"globalImportance":10,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-large-cap biotech","eventGravity":"routine_roadshow"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Genmab announced that members of its Executive Committee will participate in fireside chats at three upcoming investor conferences in September 2026.\n\nThe conferences include the Wells Fargo 21st Annual Healthcare Conference in Boston, the Morgan Stanley Global Healthcare Conference in New York City, and the Bank of America Global Healthcare Conference in London.\n\nLive and archived webcasts of these presentations will be available on the company's investor relations website.","key_figures":{},"named_entities":{"people":[{"name":"Marisol Peron","role":"Senior Vice President, Global Communications & Corporate Affairs"},{"name":"Andrew Carlsen","role":"Vice President, Head of Investor Relations"}],"products":["bispecific T-cell engagers","antibody-drug conjugates","next-generation immune checkpoint modulators","effector function-enhanced antibodies"],"companies":[{"name":"Genmab A/S","ticker":"GMAB"},{"name":"Wells Fargo","relationship":"conference organizer"},{"name":"Morgan Stanley","relationship":"conference organizer"},{"name":"Bank of America","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-25T14:42:48.944Z","global_importance":10,"audience_relevance":25,"importance_components":{"tickerTier":"mid-large-cap biotech","eventGravity":"routine_roadshow"}},"durationMs":86310,"modelName":"glm-4.7"}}